Mereo BioPharma
MREOUnited Kingdom· Est. 2015
Discover more about Mereo’s mission to improve the lives of people living with rare conditions by creating new therapeutic options.
MREO · Stock Price
USD 0.342.03 (-85.82%)
Market Cap: $56.4M
Historical price data
About
Discover more about Mereo’s mission to improve the lives of people living with rare conditions by creating new therapeutic options.
Small Molecules
Pipeline
3838 drugs in pipeline
| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Alvelestat (MPH966) | Alpha-1 Antitrypsin Deficiency (AATD) | Phase 2 | |
| BCT197 + Placebo | Pulmonary Disease, Chronic Obstructive | Phase 2 | |
| Pemetrexed + Carboplatin + demcizumab | Nonsquamous Nonsmall Cell Neoplasm of Lung | Phase 2 | |
| Nivolumab + Etigilimab | Ovarian Cancer | Phase 2 | |
| BGS649 + Placebo | Hypogonadotropic Hypogonadism | Phase 2 |